6、Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes ( Protégé study) : 1-year results from a randomised,placebo-controlled trial[J] . Lancet, 2011, 378( 9790) : 487-497
ZUMA-1 (NCT02348216) is a prospective, interventional and first multicenter, pivotal trial of an autologous anti-CD19 CAR T cell therapy, axicabtagene ciloleucel (axi-cel, formerly KTE-C19), in patients with refractory, aggressive NHL. Axi-cel treatment resulted in an ORR of 82% and a...
AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1 来自 学术范 喜欢 0 阅读量: 130 作者: SS Neelapu,FL Locke,NL Bartlett,LJ Lekakis,D Miklos,CA Jacobson,I Braunschweig,O Oluwole,T ...
teplizumab（PRV-031）预防和干预1型糖尿病（T1D）病程 teplizumab是一种研究性抗CD3单克隆抗体，开发用于拦截和预防临床T1D。该抗体已在多项临床研究中进行了评估，涉及超过1000例患者，其中超过800例患者接受了teplizumab治疗。此前在新诊患者中开展的研究显示，teplizumab持续证明了其保持β细胞功能和减少外源...
2019年8月初,Provention Bio宣布,美国食品和药物管理局(FDA)已授予teplizumab(PRV-031)突破性药物资格(BTD),这是一种单克隆抗体,用于高危群体预防或延缓发生临床1型糖尿病(T1D)。 FDA授予teplizumab BTD,是基于TrialNet开展的“At-Risk”研究的临床数据。该研究评估了teplizumab用于高危群体预防或延缓发生临床...
Interventions In each trial, patients were randomly assigned (3:1:1) to 150 mg of risankizumab, 45 mg or 90 mg of ustekinumab (weight-based per label) for 52 weeks, or matching placebo for 16 weeks followed by risankizumab. Main Outcomes and Measures Integrated data from 2 trials were...
PD-1 Antibody (Tislelizumab) Combined With VEGFR 1/2/3 Inhibitor (Fruquintinib) for ARID1A-mutated Metastatic pMMR/MSS Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial This is an open-label phase II study, with the aim of investigating the efficacy and safety of...
rate of capillary proliferation was 17.9% (7/39) for the trial. CONCLUSIONS: Our study did not meet its primary endpoint of superior ORR of unirradiated lesions with the addition of MDT to Cam in patients with R/M-NPC. 显示全部 805...
TN10替利珠单抗/Teplizumab预防T1DM的研究,由TrialNet实施,包括T1DM患者的76名亲属,他们的多种自身抗体呈阳性,且糖耐量异常。参与者被随机分配到替利珠单抗/Teplizumab(n = 44)或安慰剂(n = 32)静脉注射,疗程为14天。2019年...
This randomized clinical trial demonstrates the efficacy of 2 different dosages of galcanezumab compared with placebo in the prevention of episodic